ViroMissile clears first cohort in IV-dosed oncolytic virus Phase I

ViroMissile, Inc. has completed the first dose cohort of its ongoing first-in-human Phase I trial of IDOV-2, an intravenously delivered oncolytic virus, in patients with advanced solid tumours. The trial's independent Safety Review Committee (SRC) reviewed safety data from the cohort and cleared the study to proceed to the next, higher dose level. The trial is being conducted across sites in the United States and Australia.

The San Diego-based company reported that multiple patients in the initial cohort have achieved stable disease across several solid tumour types. Most notably, one patient has confirmed stable disease at six months following a single intravenous dose at the starting dose level. ViroMissile describes this as an early but potentially meaningful signal, given that IV-dosed oncolytic viruses have historically struggled to reach tumours efficiently before being cleared by the host immune system.

The science behind the platform

IDOV-2 is built on an engineered vaccinia strain designed to produce elevated levels of extracellular enveloped virus (EEV), a viral form that is thought to be more resistant to immune neutralisation and better able to spread between cancer cells following systemic administration. The company's thesis is that effective intravenous delivery could extend the reach of oncolytic virus therapy to metastatic and treatment-resistant cancers that are not accessible by intratumoral injection, the route used by most approved and late-stage oncolytic virus products.

Nanhai George Chen, CEO and founder, said the SRC clearance was "an important validation of the tolerability profile we've seen so far", adding that stable disease at the lowest planned dose was consistent with the company's design intent of turning the tumour into an "anti-tumour drug factory" producing cytokines and chemokines.

The Phase I open-label, multi-centre, dose-escalation study plans to enrol up to 78 adult participants. It is designed to determine the maximum tolerated dose and the recommended Phase 2 dose, with secondary objectives covering pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumour activity measures including objective response rate, disease control rate, progression-free survival, overall survival, and duration of response over a 12-month follow-up window (NCT06910657).

Market context and competitive landscape

Oncolytic virus therapy occupies a niche but increasingly active corner of the broader cancer immunotherapy market. Amgen's talimogene laherparepvec (T-VEC), an intralesional herpes simplex virus approved for advanced melanoma, remains the only oncolytic virus with regulatory approval in either the United States or Europe. Several other companies, including Replimune and Candel Therapeutics, are advancing oncolytic platforms, though most still rely on local or intratumoral injection.

ViroMissile's differentiation claim rests on the IV route, which, if borne out in subsequent cohorts, could represent a meaningful step forward in the field. However, the early Phase I data disclosed to date are limited to a tolerability read and a single case of stable disease; no objective responses have been reported. Investors and clinicians will look for dose-escalation data, pharmacokinetic profiling, and early signals of tumour shrinkage at higher dose levels before drawing firm conclusions about IDOV-2's potential. The company has not disclosed a timeline for interim data presentations or a projected Phase 2 start date.